BOSTON, MA -- January 16, 2007 --PerkinElmer Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, was recognized by International Aid, a charitable relief and development agency, at the commemoration ceremonies for an enhanced medical laboratory serving the sub-Saharan region of Africa at World AIDS Day event in December, 2006. Representatives from International Aid and MEDS Lab (MEDS), the leading medical equipment provider to developing nations, acknowledged PerkinElmer’s donation of chromatography data-handling software, interfaces, and service and support to the new MEDS laboratory in Nairobi, Kenya. This represents the first time that chromatography is being used as an analytical tool in the fight against counterfeit drugs in Africa.

“One of the acute challenges in the fight against AIDS is the proliferation of counterfeit drugs,” said Mark Heydenburg, director of medical equipment services, International Aid, Spring Lake, Michigan. “Our goal is to expose counterfeit drugs and their producers and thereby improve the treatment of some of the most medically underserved people of the world.”

The TotalChrom® Chromatography Data Systems (CDS) software package donated by PerkinElmer integrates two key technologies – gas chromatography (GC) and liquid chromatography (HPLC) – to help advance the accuracy and precision of the testing. The software is used to run PerkinElmer GC and HPLC instruments donated by pharmaceutical companies to the new MEDS laboratory.

“We are proud to contribute to this humanitarian project” said Alessandra Rasmussen, chromatography business director, PerkinElmer Life and Analytical Sciences. “We trust that the PerkinElmer contributions to the MEDS lab in Nairobi will help improve the lives of thousands of patients and their families.”

Once installed, PerkinElmer dealers in the region – who are fully trained on TotalChrom software and chromatography instrumentation – will provide ongoing support locally to ensure reliable and high-throughput operation.

Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) economic, political and other risks associated with foreign operations; (11) our ability to retain key personnel; (12) restrictions in our credit agreement; (13) our ability to realize the full value of our intangible assets; and (14) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.